General Information of Drug (ID: DMKLRCX)

Drug Name
Pedunculagin Drug Info
Synonyms Pedunculagin; CHEMBL506204; CHEBI:7948; AC1L9D8E; C10236
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
442688
ChEBI ID
CHEBI:7948
TTD Drug ID
DMKLRCX

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Coagulation factor Xa (F10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apixaban DM89JLN Thrombosis DB61-GB90 Approved [3]
Rivaroxaban DMQMBZ1 Deep vein thrombosis BD71 Approved [4]
DU-176b DMCIJBH Atrial fibrillation BC81.3 Approved [5]
Emicizumab DM0AQ83 Factor VIII deficiency 3B10 Approved [6]
BETRIXABAN DM2C4RF Venous thromboembolism BD72 Approved [7]
Lmw heparin DMJPD06 Coagulation defect 3B10.0 Approved [8]
Nadroparin calcium DMBNKST Coagulation defect 3B10.0 Approved [9]
Fondaparinux sodium DMWS3FH Deep vein thrombosis BD71 Approved [10]
Danaparoid DM6CLBN Deep venous clot BD71 Approved [11]
Coagulation Factor IX DM8HBJI Haemophilia B 3B11.0 Approved [12]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Naftifine DMHVBG1 Dermatomycosis EA60 Approved [13]
Tolnaftate DM28MU7 Dermatophytosis 1F28.2 Approved [14]
Epigallocatechin gallate DMCGWBJ Hepatic fibrosis DB93.0 Phase 3 [2]
FR-194738 DMNACIV Hypercholesterolaemia 5C80.0 Terminated [15]
SDZ-87-469 DMBY6CQ Coronary artery disease BA80 Terminated [14]
NB-598 DMJVTQN N. A. N. A. Terminated [16]
ELLAGIC ACID DMX8BS5 Discovery agent N.A. Investigative [2]
1,2,3,4,6-penta-O-galloyl-beta-D-glucose DMTK650 Discovery agent N.A. Investigative [2]
CORILAGIN DMAC698 Discovery agent N.A. Investigative [2]
ETHYLGALLATE DMJ6PB8 Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Coagulation factor IIa (F2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Argatroban DMFI46A Thrombosis DB61-GB90 Approved [17]
Pyridoxal Phosphate DMO2K0J Malnutrition 5B50-5B71 Approved [18]
Bivalirudin DMECRX1 Thrombocytopenia 3B64 Approved [19]
Ximelegatran DMU8ANS Myocardial infarction BA41-BA43 Approved [20]
Dabigatran DMDI6R4 Stroke 8B20 Approved [21]
Desirudin Recombinant DM2BTFN Coagulation defect 3B10.0 Approved [22]
Human prothrombin complex concentrate DMPHVQ1 Bleeding disorder GA20-GA21 Approved [23]
Lepirudin DM1I3D5 Thrombocytopenia 3B64 Approved [24]
Anisindione DM2C48U Coagulation defect 3B10.0 Approved [25]
ATryn antithrombin DM79Y2T Multiple sclerosis 8A40 Approved [26]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor IIa (F2) TT6L509 THRB_HUMAN Inhibitor [1]
Coagulation factor Xa (F10) TTCIHJA FA10_HUMAN Inhibitor [1]
Squalene monooxygenase (SQLE) TTE14XG ERG1_HUMAN Inhibitor [2]

References

1 Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade. J Nat Prod. 1998 Nov;61(11):1356-60.
2 Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase. J Nat Prod. 2001 Aug;64(8):1010-4.
3 Pfizer. Product Development Pipeline. March 31 2009.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2359).
6 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
7 Company report (Portola)
8 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
9 Serum zinc concentrations: contamination from laboratory equipment. JPEN J Parenter Enteral Nutr. 1979 May-Jun;3(3):179-81.
10 Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb. 2002 Sep-Dec;32(5-6):218-24.
11 Effect of factor X inhibition on coagulation activation and cytokine induction in human systemic inflammation. J Infect Dis. 2002 Nov 1;186(9):1270-6.
12 Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005 Aug;6(9):1517-24.
13 Characterization of squalene epoxidase activity from the dermatophyte Trichophyton rubrum and its inhibition by terbinafine and other antimycotic agents. Antimicrob Agents Chemother. 1996 Feb;40(2):443-7.
14 Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrob Agents Chemother. 1992 Aug;36(8):1779-81.
15 Synthesis and biological activity of a novel squalene epoxidase inhibitor, FR194738. Bioorg Med Chem Lett. 2004 Feb 9;14(3):633-7.
16 Squalene epoxidase as hypocholesterolemic drug target revisited. Prog Lipid Res. 2003 Jan;42(1):37-50.
17 Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. I. Effects on thrombin generation. J Biol Chem. 2002 Dec 27;277(52):50439-44.
18 New antithrombotic drugs (excluding plasminogen activators. Arch Mal Coeur Vaiss. 2001 Nov;94(11 Suppl):1225-32.
19 New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
20 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
21 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
23 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2362).
24 Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Kidney Int Suppl. 1999 Nov;(72):S46-50.
25 Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6.
26 Antithrombin III Utilization in a Large Teaching Hospital. P T. 2013 December; 38(12): 764-767, 779.